CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 38 enrolled
Drug / intervention
Boston Scientific Vercise PC IPG with directional DBS leaddevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03409120
NCT03409120N/ACompleted
CompareCT.gov

Unlocking Dystonia From Parkinson's Disease With Directional DBS Technology

University of Alabama at Birmingham·interventional·Posted Jan 24, 2018·Updated Nov 10, 2022

In Brief

A clinical study evaluating Boston Scientific Vercise PC IPG with directional DBS lead for Dystonia-Parkinsonism, Adult-Onset and Parkinson Disease. Completed, enrolled 38 participants across 1 site.

Detailed Summary

This study occurs during five visits that are already scheduled as part of "Biomarkers to Guide Directional DBS for Parkinson's Disease" (ClinicalTrials.gov Identifier: NCT03353688). If participants have dystonia associated with Parkinson's disease, the investigators will consent and administer one additional rating scale (Burke-Fahn-Marsden Dystonia Rating Scale) to assess the severity of dystonia.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDystonia-Parkinsonism, Adult-Onset, Parkinson Disease
CountriesUnited States
CollaboratorsMichael J. Fox Foundation for Parkinson's Research

Timeline

N/ACompletedFinished
201820192020202120222023202420252026
First PostedJan 24, 2018
Enrollment StartJan 1, 2018
Primary CompletionJun 30, 2021
Study CompletionJun 30, 2022
TodayJul 2, 2026
Enrollment to primary: 3.5 yearsPosted 8.4 years ago

Interventions

Boston Scientific Vercise PC IPG with directional DBS leaddevice

We will contrast the effects of omnidirectional versus directional STN DBS on dystonia symptoms in patients with PD.